Collplant Biotechnologies Ltd (CLGN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $14.27M
Last updated: Nov 16, 2026 at 4:00 PM ET
Collplant Biotechnologies Ltd (CLGN) Statistics
Collplant Biotechnologies (CLGN) has a market cap of $14.27M. It kept -3934.91% of revenue as net income over the last 12 months. Its share count is up 21.83% from a year earlier.
Total Valuation
| Market Cap | $14.27M |
|---|---|
| Close (Nov 16, 2026) | $4.64 |
Key Dates
The next earnings report is expected on Nov 24, 2026, covering the quarter ending Sep 30, 2026.
| Next Earnings Date | Nov 24, 2026 (expected) |
|---|---|
| Last Earnings Date | Sep 30, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 21.0x and 2.3x.
| P/S Ratio | 21.0x |
|---|---|
| Forward P/S | 2.3x |
| P/B Ratio | 2.3x |
| P/TBV Ratio | 2.3x |
Price Statistics
The stock is down 76.57% over 52 weeks and trades 19.28% above its 50-day average.
| Beta (1Y) | 1.39 |
|---|---|
| 52-Week Change | -76.57% |
| 1-Month Change | +28.00% |
| 3-Month Change | +47.58% |
| 6-Month Change | +6.72% |
| 5-Year Change | -98.12% |
| Total Return (1Y) | -76.57% |
| Total Return (3Y CAGR) | -55.34% |
| Total Return (5Y CAGR) | -52.27% |
| Return vs SPY (1Y) | -89.98% |
| Max Drawdown (1Y) | -87.82% |
| Max Drawdown (3Y) | -95.96% |
| Sharpe Ratio (1Y) | -1.21 |
| Correlation with SPY (1Y) | 0.15 |
| 50-Day Average | $3.89 |
| 200-Day Average | $4.40 |
| 52-Week Range | $2.64 to $22.50 |
| RSI (14 Days) | 61.5 |
| Average Volume (20 Days) | 38.59K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.57x current liabilities.
| Current Ratio | 1.57x |
|---|---|
| Quick Ratio | 1.35x |
Returns and Efficiency
Return on equity is -424.89% over the last 12 months, against a 5-year average of -77.79%.
| Return on Equity (ROE) | -424.89% |
|---|---|
| Return on Assets (ROA) | -173.86% |
| Return on Capital Employed (ROCE) | -262.43% |
| ROE (5Y Average) | -77.79% |
| ROA (5Y Average) | -52.04% |
| ROIC (5Y Average) | -59.57% |
| Asset Turnover | 0.03x |
| Inventory Turnover | 3.24x |
| Receivables Turnover | 2.55x |
| Cash Conversion Cycle | 173 days |
Scores
CLGN has an Altman Z-Score of -29.86, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -29.86 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $318.00K over the last 12 months is down 86.76% from the 12 months before.
| Revenue | $318.00K |
|---|---|
| Revenue Growth (YoY) | -86.76% |
| Gross Profit | -$1.66M |
| Operating Income | -$12.40M |
| Pretax Income | -$12.51M |
| Net Income | -$12.51M |
| EBITDA | -$11.52M |
| EBIT | -$12.36M |
| Reported EPS (TTM) | -$2.64 |
Trailing 12 months through Jun 30, 2026.
Balance Sheet
Shareholder equity funds 40.83% of the $7.20M in total assets.
| Cash and Equivalents | $2.95M |
|---|---|
| Working Capital | $1.41M |
| Shareholder Equity | $2.94M |
| Tangible Book Value | $2.90M |
| Total Assets | $7.20M |
| Total Liabilities | $4.25M |
Balance sheet as of Jun 30, 2026.
Cash Flow
After $94.03K of capital spending, operating cash flow left -$11.70M of free cash flow.
| Operating Cash Flow | -$11.61M |
|---|---|
| Capital Expenditures | $94.03K |
| Free Cash Flow | -$11.70M |
| FCF Per Share | -$3.80 |
| Depreciation and Amortization | $846.00K |
Trailing 12 months through Jun 30, 2026.
Margins
The operating margin is -3900.94%.
| Gross Margin | -521.70% |
|---|---|
| Operating Margin | -3900.94% |
| Pretax Margin | -3934.91% |
| Net Margin | -3934.91% |
| EBITDA Margin | -3621.70% |
| EBIT Margin | -3887.74% |
| FCF Margin | -3679.61% |
Growth
Revenue grew 99.41% a year over 3 years.
| Revenue Growth (3Y CAGR) | +99.41% |
|---|---|
| Revenue Growth (5Y CAGR) | -17.32% |
Dividends and Yields
CLGN does not pay a dividend. Its free cash flow yield is -174.81%.
| FCF Yield | -174.81% |
|---|---|
| Shareholder Yield | 0.00% |
Stock Splits
The last split was a 1-for-10 reverse split on Sep 4, 2026.
| Last Split Date | Sep 4, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:10 |
Peer Position
Against 6 similar companies, CLGN has the highest P/S.
P/S RatioPeer median 4.3x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -47.96%
| P/S Ratio | 21.0x vs 4.3x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -86.76% vs -47.96% median |
Analyst Forecast
Consensus estimates put revenue growth at 11.03% a year over the next 5 fiscal years.
| Revenue Growth Forecast (5Y CAGR) | +11.03% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About CLGN
What is CLGN's market cap?
Collplant Biotechnologies has a market cap of $14.27M.
How many shares of CLGN are outstanding?
Collplant Biotechnologies has 1.44M shares outstanding. The count is up 21.83% from a year earlier.
Does CLGN pay a dividend?
No. Collplant Biotechnologies does not pay a dividend.
CLGN pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors